Amylyx Pharmaceuticals (AMLX) Research & Development (2021 - 2025)
Historic Research & Development for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to $19.9 million.
- Amylyx Pharmaceuticals' Research & Development fell 650.75% to $19.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $92.1 million, marking a year-over-year decrease of 2697.97%. This contributed to the annual value of $104.1 million for FY2024, which is 1880.3% down from last year.
- As of Q3 2025, Amylyx Pharmaceuticals' Research & Development stood at $19.9 million, which was down 650.75% from $27.2 million recorded in Q2 2025.
- Over the past 5 years, Amylyx Pharmaceuticals' Research & Development peaked at $44.9 million during Q4 2023, and registered a low of $6.9 million during Q1 2021.
- Moreover, its 5-year median value for Research & Development was $22.9 million (2024), whereas its average is $23.1 million.
- Its Research & Development has fluctuated over the past 5 years, first soared by 21270.4% in 2022, then crashed by 4903.15% in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Research & Development stood at $13.4 million in 2021, then skyrocketed by 70.32% to $22.8 million in 2022, then skyrocketed by 96.88% to $44.9 million in 2023, then tumbled by 49.03% to $22.9 million in 2024, then fell by 13.27% to $19.9 million in 2025.
- Its Research & Development was $19.9 million in Q3 2025, compared to $27.2 million in Q2 2025 and $22.1 million in Q1 2025.